Relapse rates in schizophrenic patients are still high although we have been using atypical antipsychotics now for a couple of years. Recent studies have shown that compliance rates were more or less unaffected by the invention of the atypical antipsychotics. Long acting depots, providing substantial advantages in maintaining patient's compliance, were only available for conventional antipsychotics. The introduction of an atypical long acting antipsychotic to the market raises new questions and demands reconsideration of our treatment strategies.